MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.21
+0.34
+6.98%
After Hours: 5.04 -0.17 -3.26% 16:04 05/27 EDT
OPEN
4.890
PREV CLOSE
4.870
HIGH
5.23
LOW
4.790
VOLUME
940.71K
TURNOVER
0
52 WEEK HIGH
20.04
52 WEEK LOW
4.610
MARKET CAP
486.64M
P/E (TTM)
-1.4288
1D
5D
1M
3M
1Y
5Y
Where Atara Biotherapeutics Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Atara Biotherapeutics (NASDAQ:ATRA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will tr...
Benzinga · 3d ago
--Goldman Sachs Adjusts Atara Biotherapeutics' Price Target to $4 from $5, Keeps Sell Rating
MT Newswires · 4d ago
Atara price target lowered at H.C. Wainwright as partnership with Bayer ends
Atara Biotherapeutics (NASDAQ:ATRA), a biotech focused on immunotherapies, continues to trade lower on Monday after announcing that German conglomerate Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) decided to end a licensing deal with the
Seekingalpha · 5d ago
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
Benzinga · 5d ago
HC Wainwright & Co. Maintains Buy Rating for Atara Biotherapeutics: Here's What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00. Shares of Atara Biotherapeutics are trading down 3.1% over the last 24 hours, at $5.00 per share.
Benzinga · 5d ago
HC Wainwright Adjusts Atara Biotherapeutics' Price Target to $29 from $31, Keeps Buy Rating
MT Newswires · 5d ago
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Benzinga · 05/20 10:49
Bayer to end collaboration with Atara Biotherapeutics to develop CAR T-cell therapies
Atara Biotherapeutics (NASDAQ:ATRA) on Thursday said its collaboration partner Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) had decided to end the exclusive worldwide licensing agreement between the companies to develop CAR T-cell therapies. ATRA
Seekingalpha · 05/19 20:13
More
No Data
Learn about the latest financial forecast of ATRA. Analyze the recent business situations of Atara Biotherape through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

22.22%Strong Buy
55.56%Buy
11.11%Hold
11.11%Under-perform
0.00%Sell
Analyst Price Target
The average ATRA stock price target is 27.29 with a high estimate of 67.00 and a low estimate of 5.00.
High67.00
Average27.29
Low5.00
Current 5.21
EPS
Actual
Estimate
-0.78-0.59-0.39-0.20
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 203
Institutional Holdings: 99.23M
% Owned: 106.23%
Shares Outstanding: 93.41M
TypeInstitutionsShares
Increased
51
7.99M
New
16
2.89M
Decreased
47
5.02M
Sold Out
15
988.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Ronald Renaud
President/Chief Executive Officer/Director
Pascal Touchon
Chief Financial Officer/Executive Vice President
Utpal Koppikar
Executive Vice President
Jakob Dupont
Senior Vice President/General Counsel
K. Amar Murugan
Senior Vice President
Kristin Yarema
Chief Technology Officer
Charlene Banard
Independent Director
Roy Baynes
Independent Director
Eric Dobmeier
Independent Director
Matthew Fust
Independent Director
Carol Gallagher
Independent Director
William Heiden
Independent Director
Ameet Mallik
Independent Director
Maria Roncarolo
Independent Director
Beth Seidenberg
No Data
No Data
About ATRA
Atara Biotherapeutics, Inc. is engaged in developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease. The Company’s pipeline products include Tab-cel and ATA188, as well as ATA2271, ATA3271 and ATA3219 under CAR T Programs. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. The Company’s ATA188 is a T-cell immunotherapy targeting EBV antigens for the treatment of multiple sclerosis. Its ATA2271 is an autologous chimeric antigen receptors (CAR) T immunotherapy targeting solid tumors expressing the tumor antigen mesothelin.

Webull offers kinds of Atara Biotherapeutics Inc stock information, including NASDAQ:ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.